The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, ...

BOSTON--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced exciting preliminary Phase 1 clinical data for its lead investigational candidate ...

Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting –Favorable safety and tolerability ...

Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced exciting preliminary Phase 1 clinical data for its lead investigational candidate, STX-001, in patients with ...

In the ongoing first-in-human Phase 1, open-label, dose-escalation clinical trial, STX-001 demonstrated a favorable safety profile and encouraging signs of anti-tumor activity as a monotherapy in ...

today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant ...

today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant ...

"Our findings of increased CKD risk in COVID-19 patients without initial AKI suggest mechanisms distinct from acute damage pathways," they wrote. "This phenomenon can be explained by several ...